Larimar Therapeutics, Inc. (NASDAQ:LRMR) released initial data from the ongoing long-term OLE study evaluating daily ...

inherited neuromuscular disease caused by mutations in a gene called FXN that leads to impaired muscle coordination, as well as problems with the heart and central nervous system. Earlier this ...

Buy FXN near 17.44 target 18.75 stop loss @ 17.39 Details The technical summary data tells us to buy FXN near 17.44 with an upside target of 18.75. This data also tells us to set a stop loss @ 17.39 ...

Early attempts to treat FRDA with antioxidants, before the FXN gene was discovered, were prompted by a generic assumption that oxidative stress contributes to neurodegeneration, as well as by the ...

In the assessment of 12-month price targets, analysts unveil insights for Voyager Therapeutics, presenting an average target ...

Treatment with nomlabofusp modified gene expression and lipid profiles in addition to increasing frataxin – FXN – levels in study participants with Friedreich’s ataxia. Modeling and ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others. Financial Milestones: Voyager Therapeutics's Journey Market ...

After Natalie Rex was diagnosed with Friedreich’s ataxia -- a rare genetic and usually fatal neurological disease -- her twin sister, Melanie, became her roommate and caregiver.